Needham has downgraded Cidara Therapeutics Inc (CDTX) to Hold from Buy, effective November 13, 2025. The stock is currently priced at $217.71.
This downgrade suggests increased caution regarding Cidara's outlook, potentially reflecting concerns about competitive pressures and execution risks that may affect the company's performance.
Cidara Therapeutics, based in San Diego, California, develops targeted immunotherapies aimed at improving the standard of care for patients with serious diseases. The firm utilizes its Cloudbreak platform to create drug-Fc conjugates (DFCs), including its lead candidate CD388, an antiviral designed for universal prevention and treatment of influenza, which has completed Phase I and Phase IIa clinical trials.
The company's financial snapshot shows a market cap of $2.5 billion and a trailing twelve-month EPS of -11.12. Upcoming earnings are scheduled for May 5, 2026, and August 4, 2026. Recent earnings performance has shown some surprises, including a Q2 2025 EPS of -1.65, beating estimates by 18.7%.
Analyst consensus currently stands at 4 Strong Buy, 10 Buy, 1 Hold, and no Sell or Strong Sell ratings, indicating a general positive outlook despite the recent downgrade.